MetAlert (OTC: MLRT) is a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. “MetAlert is looking to achieve ‘some big things’ in 2023. Speaking in an interview with Sequire Spotlight published Dec. 28, CEO Patrick Bertagna outlined the company’s strategic plans for 2023. MetAlert, he explained, is ‘looking at making some acquisitions, bringing on some new products, and possibly doing an uplist,’ with the acquisitions, in particular, intended to align with the company’s existing subscription model and increase the revenue per user (‘RPU’),” a recent article reads. “MetAlert recently announced it had signed a letter of intent (‘LOI’) to acquire TrakTec LLC, a Florida-based manufacturer and seller of affordable location awareness technology solutions for consumer, enterprise and government applications, for a consideration of $4.5 million in cash and stock… According to Bertagna, MetAlert anticipates the acquisition will offer both short- and long-term benefits. ‘Short-term, this will grow our existing subscriber base, increase revenues and expand our product offering,’ he explained. ‘Longer term, we will have more capability to develop new products, grow the government and police department sales channels, have a sales and support presence on the East Coast, and accelerate the company’s growth as we work toward a possible 2023 uplist to a national exchange.’”
To view the full article, visit https://ibn.fm/Lg1tE
About MetAlert Inc.
MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring sectors. With over 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technologies, caregivers are enabled to track and monitor patients in real time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers around the globe with subscribers in over 40 countries. MetAlert is a U.S. military government contractor and has other customers that include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.